# Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

> **NCT00657007** · PHASE1 · COMPLETED · sponsor: **Human Genome Sciences Inc.** · enrollment: 70 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** belimumab
- **BIOLOGICAL:** belimumab
- **BIOLOGICAL:** belimumab
- **BIOLOGICAL:** belimumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00657007
- **Lead sponsor:** Human Genome Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00657007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00657007, "Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00657007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*